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ABSTRACT
Aims: In clinical trials, disability progression in multiple sclerosis (MS) is measured by the Kurtzke
expanded disability status scale (EDSS), which is not captured in routine clinical care in the U.S. This
study developed a claims-based disability score (CDS) based on the EDSS for assigning MS disability
level in a U.S. claims database.
Methods: This retrospective cohort study of patients with MS in the U.S., utilized adjudicated health
plan claims data linked to electronic medical records (EMRs) data. Patients were identified between 1
January 2012 and 31 December 2016 and indexed on the first date of MS diagnosis. The CDS was
developed to assign disability level at baseline using claims and ambulatory EMR records observed
over the 1-year baseline period. All-cause healthcare costs were assessed by baseline disability level to
validate the CDS.
Results: In total, 45,687 patients were identified in claims (full sample) and 1,599 linked to EMR (core
sample). Over half of patients in both samples were classified with mild disability at baseline. Adjusted
healthcare costs in patients with moderate and severe disability were 15% (p<.0001) and 20% higher,
respectively, than in patients with mild disability at baseline in the full sample. Disease-modifying ther-
apy (DMT) costs accounted for 89%, 82%, and 78% of outpatient pharmacy costs in patients with
mild, moderate, and severe disability, respectively.
Conclusions: The CDS is the first claims-based measure of MS disability utilizing data from EMR. This
novel measure advances the opportunity to examine outcomes by disability accumulation in the
absence of standard markers of disease progression. Although formal validation of the CDS was not
possible due to lack of available EDSS in the EMR, the economic burden results align with prior publi-
cations and show that healthcare costs increase with increasing disability. Future validation studies of
the CDS are warranted.
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Background
Multiple sclerosis (MS) is the most common cause of neuro-
logical disability in adults of working age, and is character-
ized by inflammation, demyelination, gliosis, and axonal
destruction throughout the central nervous system1,2. In
2016, an estimated 2.2 million people worldwide had MS,
corresponding to a prevalence of 30.1 cases per 100,000
population3. In the U.S., the incidence of MS is estimated to
be 2.0 cases per 100,000 person-years in men and 3.6 in
women4. MS is a very costly chronic disease based on prior
analyses using privately insured claims databases, with direct
and indirect costs (including costs of disease-related absen-
ces from work, short- and long-term disability) that approxi-
mately comprised 77% (range 64–91%) and 23% (range
9–36%) of total healthcare costs, respectively5,6.
MS disability progression is most commonly measured by
the expanded disability status scale (EDSS) in clinical trials7.
The EDSS is a clinician-based instrument that includes assess-
ment of seven functional systems (plus “other”) including
pyramidal, cerebellar, brainstem, bowel and bladder, sensory,
visual, and cerebral. The score is reported in half point incre-
ments from 0 (with no disability due to MS) to 10 (death
due to MS) based on neurological and physical examina-
tions8. Other important EDSS cut-offs include: 6 (requires a
walking aid such as a cane or crutch), 7 (restricted to wheel-
chair), 8 (restricted to bed/chair), and 9 (confined to bed).
Even while the EDSS is the gold standard in measuring dis-
ability in the clinical trial setting, it is not typically used in
routine clinical care in the US. As such, it is not reliably
found in secondary data sources used for health-outcomes
research, such as EHRs or administrative claims, making it
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difficult to capture the economic burden of advancing MS
disease. As such, this is still an evidence gap, with limited lit-
erature on methods to assign or approximate MS disability
levels in administrative healthcare claims data. A prior study
by Munsell et al. developed a claims-based measure as an
indicator of disease status based on healthcare costs9, how-
ever, the results were not corroborated with clinical meas-
ures of disability, such as the EDSS.
Establishing the level of MS disability progression in real-
world evidence studies presents researchers with a challenge,
as the majority of available claims and electronic medical
record (EMR) databases do not routinely contain EDSS score.
Indeed, per our initial estimate, less than 1% of EMR records
contained the EDSS number. To overcome this limitation, this
study developed a claims-based disability score (CDS) to char-
acterize disability status using the eight functional systems
that comprise the EDSS using EMR data linked to adjudicated
healthcare claims, with the guidance of physicians who spe-
cialize in the treatment of MS. This methodology leverages
both claims and narrative EMR information to enhance prior
efforts that have used claims only and allows MS patients
characterization by disability level in real world settings.
Methods
This was a retrospective cohort study of patients with MS in
the U.S. identified between 1 January 2012 and 31
December 2016. Disability level was characterized by obser-
vation of proxies for ambulation/functional status in claims
(e.g. wheelchair claim, diagnosis of urinary incontinence),
and vitals/problem lists in the EMR (e.g. visual disturbance,
tactile sensation). Patients were stratified into approximate
disability levels, consistent with their observed characteristics
during the 1-year pre-index period and as aligned with the
underlying continuum of disability as represented in the
EDSS. Demographic information was collected at index date,
and included age, sex, geographic region, and payer type.
Clinical characteristics were collected during the 1-year pre-
index period, and included the Charlson comorbidity index
(CCI), common comorbidities, MS-related medication use, MS
relapse, and MS-related symptoms and secondary conditions.
MS relapse was defined as having an inpatient hospitaliza-
tion with a primary diagnosis of MS or having a claim for an
oral or intravenous corticosteroid within seven days after an
MS-related outpatient visit10. The study utilized secondary
data from the IQVIA PharMetrics Plusi database which was
linked to IQVIA’s Ambulatory EMR (AEMR) data.
Patient selection
The study consisted of two main study cohorts: the full sam-
ple, which comprised all eligible MS patients identified in
PharMetrics Plus; and the core sample, which included MS
patients identified in PharMetrics Plus who linked to
AEMR data.
The full sample included patients with at least two out-
patient claims (30 days apart) with a diagnosis code for MS
or 1 inpatient claim with a primary diagnosis of MS
observed between 1 January 2012 and 31 December 2016.
The date of the first MS diagnosis occurring during this win-
dow was the index date. Patients had 1 year of continuous
health plan enrollment with pharmacy and medical benefits
prior to and after the index date, were 20 years of age on
the index date and had no data quality issues in the claims
database. The core sample consisted of a subset of patients
from the full sample who linked to the AEMR database and
had at least one diagnosis record of MS or evidence of dis-
ease-modifying therapy (DMT) in the AEMR between 1
January 2011 and 31 December 2017. Patients in the core
sample were also required to have at least one visit record
in the AEMR database within one year prior to the index
date to assess pre-index disability.
Development of EDSS-based disability criteria
The CDS was developed in a series of steps, with guidance
from four medical experts (MEs); three of whom are physi-
cians specializing in MS treatment, and one of whom is a
medical director at the sponsoring institution. As a first step,
an initial list of broad terms related to MS symptomology
and the EDSS criteria was developed. These terms were then
searched for in two tables of the AEMR database: the prob-
lem list and the vitals tables and the list was further refined
based on the data. The problem list table contains all diag-
noses recorded by a physician during a clinical encounter,
while the vitals table contains data on patient vitals, timed
walk results, and orders for durable medical equip-
ment (DME).
After finalizing the list, terms were mapped to EDSS and
functional system score (FSS) categories which included:
bowel and bladder, brainstem, cerebellar, cerebral, pyramidal,
sensory, visual function, other. Three MEs then independently
assigned a severity score to each term, based on their clinical
opinion. Scores ranged from 1 (mild) to 3 (severe). In cases
of disagreement between MEs, the final severity score for a
term was established based on a majority ruling.
Next, terms for diagnoses were mapped to International
Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM), International Classification of Diseases, Tenth
Revision, Clinical Modification (ICD-10-CM), terms related to
procedures and DME were mapped to Current Procedural
Terminology (CPT). Three MEs independently assigned a
severity score to each clinical code, based on code descrip-
tions and their clinical opinion. As previously, a majority rul-
ing determined the final score for each code in cases of
disagreement.
After identifying the two study populations, the AEMR
records and claims for each patient were assessed for the
occurrence of the terms/billing codes occurring during the 1-
year pre-index period. The CDS at baseline was defined using
the following hierarchy:
 Severe: Defined as having 1 EDSS-related symptom with
severity score ¼ 3 in any functional system;
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 Moderate: Defined as having 1 EDSS-related symptom
with severity score ¼ 2 in any functional system, or hav-
ing 2 functional systems with severity score ¼ 1;
 Mild: Defined as having only one EDSS-related symptom
with severity score ¼ 1 or having no EDSS-related symp-
toms observed during the measurement period.
For patients with additional years of follow-up available,
the disability level was re-assessed at year 1 and year 2 post-
index. Values could not regress to a lower disability level. In
other words, if a patient’s disability level was considered
moderate at baseline, the patient could not be considered
mild at year one.
Finally, as an informal validation of the CDS, total health-
care costs accrued during the 1-year post-index period was
calculated for each patient in the full sample to assess
whether the expected trend of cost increasing with increas-
ing disability level was observed. Total healthcare costs
included medical and outpatient pharmacy costs, including
DMT infusions. The proportion of outpatient pharmacy costs
attributable to DMTs was also assessed. In patients with add-
itional years of follow-up, healthcare costs were calculated in
each year after disability level was established. Unadjusted
costs were calculated by summing the allowed amount on
all claims occurring during the 1-year post-index period. All
costs were adjusted to 2018 dollars using the healthcare
component of the Consumer Price Index.
Statistical methods
Chi-square tests were used to compare categorical demo-
graphic and clinical variables by disease severity. For continu-
ous measures, t-test and analysis of variance (ANOVA) were
used to make comparisons by disease severity.
A generalized linear model with gamma distribution and
log link function11,12 was developed to assess differences in
cost by disability level. The outcome was total all-cause
healthcare costs accrued over the fixed one-year post-index
period. Independent variables in the model included: base-
line disability level, age category, sex, region, CCI, pre-index
use of DMTs, pre-index occurrence of MS relapse, and the
log of pre-index total all-cause healthcare cost. Wald chi-
square tests were used to compare costs between patients
with mild versus moderate or severe disability. The adjusted
mean healthcare costs in patients with mild, moderate, and
severe MS disability were estimated using the recycle predic-
tion method13 and the standard error of the means were cal-
culated using bootstrapping with 1,000 repetitions14.
Results
A total of 45,687 and 1,599 eligible patients were included in
the full sample and core sample, respectively (Figure 1).
Patients in the full sample had a mean age of 49 and 76% of
the study population was female (Table 1). Most reflected
mild disability at index (mild: 66%, moderate: 22%, severe:
13%). The core sample had similar baseline characteristics as
the full sample (mean age: 49 years; 78% female) with a
slightly higher proportion of patients having moderate dis-
ability per the CDS (28%) and lower proportion having mild
disability (58%) (Table 2). The remaining results reported are
for the full sample.
The mean (standard deviation (SD)) 1-year total
unadjusted all-cause healthcare costs ranged from $45,574
(39,908) in patients with mild disability to $60,567 (61,880) in
patients with severe disability at baseline, with a significant
associated observed between cost and disability level
(p<.0001). Healthcare costs were largely driven by outpatient
pharmacy costs, most of which was due to the cost of DMTs.
In patients with mild disability, 89% of outpatient pharmacy
costs were due to DMTs (DMT costs: $30,555 (27,984)). In
patients with moderate disability, DMTs accounted for 82%
Figure 1. Patient attrition.
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Table 1. Characteristics of the full sample.
Full sample patients Patients with 1-year post-index eligibility
Mild disability Moderate disability Severe disability p Value
(N¼ 45,687) (n¼ 29,972) (n¼ 9,916) (n¼ 5,799)
Age group (n, %)
20–34 years 5,595 12.2% 3,914 13.1% 1,095 11.0% 586 10.1% <.0001
35–44 years 10,505 23.0% 7,351 24.5% 2,084 21.0% 1,070 18.5%
45–54 years 14,901 32.6% 9,951 33.2% 3,219 32.5% 1,731 29.9%
55–64 years 12,367 27.1% 7,575 25.3% 2,924 29.5% 1,868 32.2%
65þ years 2,319 5.1% 1,181 3.9% 594 6.0% 544 9.4%
Age (continuous)
Mean 48.5 47.7 49.4 50.9 <.0001
SD 11.1 10.9 11.2 11.8
Median 49 48 50 52
Gender (n, %)
Male 10,985 24.0% 7,082 23.6% 2,527 25.5% 1,376 23.7% .0007
Female 34,702 76.0% 22,890 76.4% 7,389 74.5% 4,423 76.3%
Geographic region (n, %)
Northeast 13,055 28.6% 8,606 28.7% 2,828 28.5% 1,621 28.0% <.0001
Midwest 14,377 31.5% 9,562 31.9% 2,996 30.2% 1,819 31.4%
South 12,441 27.2% 7,944 26.5% 2,893 29.2% 1,604 27.7%
West 4,992 10.9% 3,261 10.9% 1,065 10.7% 666 11.5%
Unknown 822 1.8% 599 2.0% 134 1.4% 89 1.5%
Payer type (n, %)
Commercial/self-insured 43,212 94.6% 28,517 95.1% 9,420 95.0% 5,275 91.0% <.0001
Medicaid 1,420 3.1% 825 2.8% 286 2.9% 309 5.3%
Medicare 734 1.6% 402 1.3% 153 1.5% 179 3.1%
Unknown 321 0.7% 228 0.8% 57 0.6% 36 0.6%
Index year (n, %)
2012 32,111 70.3% 21,013 70.1% 6,981 70.4% 4,117 71.0% <.0001
2013 4,822 10.6% 3,409 11.4% 904 9.1% 509 8.8%
2014 3,267 7.2% 2,109 7.0% 717 7.2% 441 7.6%
2015 3,480 7.6% 2,293 7.7% 714 7.2% 473 8.2%
2016 2,007 4.4% 1,148 3.8% 600 6.1% 259 4.5%
Charlson comorbidity index (CCI) (n, %)
0 31,982 70.0% 22,839 76.2% 6,256 63.1% 2,887 49.8% <.0001
1 7,737 16.9% 4,673 15.6% 1,926 19.4% 1,138 19.6%
2 3,613 7.9% 1,673 5.6% 1,017 10.3% 923 15.9%
3 1,229 2.7% 431 1.4% 406 4.1% 392 6.8%
4þ 1,126 2.5% 356 1.2% 311 3.1% 459 7.9%
Mean 0.5 0.4 0.7 1.1 <.0001
SD 1.1 0.9 1.2 1.6
Median 0 0 0 1
Common comorbid conditions (n, %)
Chronic pain/fibromyalgia 5,588 12.2% 2,625 8.8% 1,848 18.6% 1,115 19.2% <.0001
Diabetes 3,875 8.5% 2,113 7.0% 974 9.8% 788 13.6% <.0001
Dyslipidemia 12,793 28.0% 7,600 25.4% 3,162 31.9% 2,031 35.0% <.0001
Hypertension 12,402 27.1% 7,142 23.8% 3,130 31.6% 2,130 36.7% <.0001
Osteoarthritis 19,582 42.9% 10,553 35.2% 5,934 59.8% 3,095 53.4% <.0001
Smoking or history of smoking 3,962 8.7% 2,183 7.3% 1,013 10.2% 766 13.2% <.0001
Thyroid disease 5,826 12.8% 3,473 11.6% 1,471 14.8% 882 15.2% <.0001
MS-related medication use (n, %)
Any disease-modifying therapy (DMT) use 21,487 47.0% 14,701 49.0% 4,427 44.6% 2,359 40.7% <.0001
Alemtuzumab 1 0.0% 0 0.0% 1 0.0% 0 0.0% .3191
Daclizumab 1 0.0% 0 0.0% 1 0.0% 0 0.0% .3184
Dimethyl fumarate 148 0.7% 113 0.8% 26 0.6% 9 0.4% .0709
Fingolimod 1,332 6.2% 815 5.5% 330 7.5% 187 7.9% <.0001
Glatiramer acetate 8,322 38.7% 5,626 38.3% 1,774 40.1% 922 39.1% .0907
Interferon b-1a 8,434 39.3% 6,043 41.1% 1,582 35.7% 809 34.3% <.0001
Interferon b-1b 2,168 10.1% 1,477 10.0% 457 10.3% 234 9.9% .8308
Mitoxantrone 27 0.1% 9 0.1% 10 0.2% 8 0.3% .0002
Natalizumab 2,210 10.3% 1,224 8.3% 591 13.3% 395 16.7% <.0001
Pegylated interferon b-1a 11 0.1% 9 0.1% 1 0.0% 1 0.0% .7987
Teriflunomide 28 0.1% 25 0.2% 3 0.1% 0 0.0% .0452
Rituximab 119 0.6% 53 0.4% 36 0.8% 30 1.3% <.0001
No DMT use 24,200 53.0% 15,271 51.0% 5,489 55.4% 3,440 59.3% <.0001
Baclofen 5,514 12.2% 2,270 7.7% 1,834 18.5% 1,410 24.3% <.0001
Relapse
Patients with a relapse in inpatient or outpatient setting (n, %) 5,995 13.1% 2,640 8.8% 1,853 18.7% 1,502 25.9% <.0001
Number of relapses in all patients
Mean 0.4 0.2 0.5 1.1 <.0001
SD 1.9 0.9 1.8 4.1
Median 0.0 0.0 0.0 0.0
(continued)
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of outpatient pharmacy costs (DMT costs: $30,212 (28,320)).
Finally, DMT costs accounted for 78% of outpatient phar-
macy costs in patients with severe disability at baseline (DMT
costs: $27,251 (28,968)).
Adjusted total annual healthcare costs (mean± SE) were
highest among severe patients: $56,206 ± 87, followed by
moderate: $53,488 ± 83, and mild: $46,691 ± 72 (Figure 2).
Comparison across disability level showed that adjusted total
annual healthcare costs were 15% (p.0001) and 20%
(p<.0001) higher in moderate and severe than mild patients,
respectively.
Discussion
To our knowledge, this is the first published study to
develop a measure of MS disability in claims data that prox-
ies the EDSS, which is considered the gold standard disability
assessment and endpoint in clinical trials. Key medical
expertise in using EMR narrative and claims data to approxi-
mate disability level was central in this process including
alignment on potential proxy indicators, a priori, followed by
rigorous review of the resulting groupings by internal and
external MEs. Overall, higher disability level per the CDS was
associated with increased total all-cause 1-year post-index
healthcare cost, for both unadjusted and adjusted cost analy-
ses. The increase in total cost at higher disability levels was
due to increases in both medical and outpatient phar-
macy costs.
While pharmacy costs increased between patients with
mild and moderate disability and leveled-off, medical costs
increased steadily from one disability level to the next. Jones
et al. which quantified the relationship between increased
disability and health care resource utilization, quality of life,
work productivity, and health care costs in patients with MS
also found increased disability was associated with increased
health care resource utilization and costs. The finding of this
study using the proxy measure of MS disability was consist-
ent with finding from the study by Jones et al. in which
EDSS score was used to measure disability15. Similarly, Kobelt
et al. reported that costs for severely disabled individuals
were more than twice those for persons with relatively mild
disease16. Compared to an individual with an EDSS score of
2, costs for an individual with an EDSS score of 8 are almost
three times as high17. In addition, an observational, cross-sec-
tional multi-country study which collected information on
16,808 patients’ characteristics, disease type, use of resources
and loss of resource and used EDSS to stratify patients by
disease level also showed the relationship between costs
and disability, that costs increased on average fivefold
between mild and severe MS18.
While total healthcare costs increased, the proportion of
pharmacy costs attributed to DMTs decreased with
Table 1. Continued.
Full sample patients Patients with 1-year post-index eligibility
Mild disability Moderate disability Severe disability p Value
(N¼ 45,687) (n¼ 29,972) (n¼ 9,916) (n¼ 5,799)
MS-related symptoms and secondary conditions (n, %)
Anxiety 4,973 11.0% 2,593 8.8% 1,428 14.4% 952 16.4% <.0001
Depression 7,650 17.0% 3,909 13.3% 2,085 21.0% 1,656 28.6% <.0001
Eye symptoms 1,518 3.4% 601 2.0% 539 5.4% 378 6.5% <.0001
Fatigue 10,783 23.9% 5,165 17.6% 3,359 33.9% 2,259 39.0% <.0001
Fractures 142 0.3% 48 0.2% 56 0.6% 38 0.7% <.0001
Irritable bowel syndrome 906 2.0% 474 1.6% 281 2.8% 151 2.6% <.0001
Muscular weakness 3,504 7.8% 0 0.0% 2,330 23.5% 1,174 20.2% <.0001
Osteoporosis 1,544 3.4% 709 2.4% 455 4.6% 380 6.6% <.0001
Pyramidal symptoms 5,720 12.7% 0 0.0% 4,111 41.5% 1,609 27.7% <.0001
Sensory problems 9,249 20.5% 4,644 15.8% 2,994 30.2% 1,611 27.8% <.0001
Sleep disturbance 4,732 10.5% 2,362 8.0% 1,447 14.6% 923 15.9% <.0001
Figure 2. Adjusted healthcare costs by baseline disability level in the full sample (n¼ 45,687). The patterned portion of the pharmacy costs indicates costs associ-
ated with DMT use.
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Table 2. Characteristics of the core sample.
Core sample patients Patients with 1-year post-index eligibility
Mild disability Moderate disability Severe disability p Value(N¼ 1,599)
(n¼ 931) (n¼ 442) (n¼ 226)
Age group (n, %)
20–34 years 160 10.0% 105 11.3% 38 8.6% 17 7.5% <.0001
35–44 years 358 22.4% 241 25.9% 76 17.2% 41 18.1%
45–54 years 524 32.8% 288 30.9% 169 38.2% 67 29.6%
55–64 years 489 30.6% 268 28.8% 132 29.9% 89 39.4%
65þ years 68 4.3% 29 3.1% 27 6.1% 12 5.3%
Age (continuous)
Mean 49.3 48.2 50.4 51.3 <.0001
SD 10.7 10.6 10.7 10.6
Median 50 49 51 54
Gender (n, %)
Male 352 22.0% 201 21.6% 105 23.8% 46 20.4% .5376
Female 1,247 78.0% 730 78.4% 337 76.2% 180 79.6%
Geographic region (n, %)
Northeast 764 47.8% 447 48.0% 225 50.9% 92 40.7% .0003
Midwest 347 21.7% 222 23.8% 86 19.5% 39 17.3%
South 332 20.8% 184 19.8% 79 17.9% 69 30.5%
West 156 9.8% 78 8.4% 52 11.8% 26 11.5%
Payer type (n, %)
Commercial/self-insured 1,528 95.6% 903 97.0% 414 93.7% 211 93.4% .0115
Medicaid 14 0.9% 7 0.8% 5 1.1% 2 0.9%
Medicare 57 3.6% 21 2.3% 23 5.2% 13 5.8%
Index year (n, %)
2012 1,277 79.9% 750 80.6% 357 80.8% 170 75.2% .0123
2013 129 8.1% 87 9.3% 23 5.2% 19 8.4%
2014 89 5.6% 48 5.2% 28 6.3% 13 5.8%
2015 66 4.1% 29 3.1% 20 4.5% 17 7.5%
2016 38 2.4% 17 1.8% 14 3.2% 7 3.1%
Charlson comorbidity index (CCI) (n, %)
0 1,127 70.5% 718 77.1% 287 64.9% 122 54.0% <.0001
1 249 15.6% 141 15.2% 73 16.5% 35 15.5%
2 132 8.3% 52 5.6% 48 10.9% 32 14.2%
3 50 3.1% 14 1.5% 16 3.6% 20 8.9%
4þ 41 2.6% 6 0.6% 18 4.1% 17 7.5%
Mean 0.6 0.3 0.7 1.2 <.0001
SD 1.2 0.8 1.3 1.8
Median 0 0 0 0
Common comorbid conditions (n, %)
Chronic pain/fibromyalgia 189 11.8% 74 8.0% 72 16.3% 43 19.0% <.0001
Diabetes 140 8.8% 61 6.6% 45 10.2% 34 15.0% .0001
Dyslipidemia 494 30.9% 245 26.3% 167 37.8% 82 36.3% <.0001
Hypertension 440 27.5% 221 23.7% 141 31.9% 78 34.5% .0003
Osteoarthritis 688 43.0% 348 37.4% 237 53.6% 103 45.6% <.0001
Smoking or history of smoking 145 9.1% 67 7.2% 44 10.0% 34 15.0% .0008
Thyroid disease 243 15.2% 132 14.2% 64 14.5% 47 20.8% .0403
MS-related medication use (n, %)
Any disease-modifying therapy (DMT) use 938 58.7% 576 61.9% 256 57.9% 938 58.7% .0039
Dimethyl fumarate 2 0.2% 1 0.2% 0 0.0% 1 0.9% .2863
Fingolimod 49 5.2% 23 4.0% 12 4.7% 14 13.2% .0004
Glatiramer acetate 365 39.0% 221 38.4% 109 42.7% 35 33.0% .2045
Interferon b-1a 393 42.0% 257 44.7% 98 38.4% 38 35.8% .0956
Interferon b-1b 84 9.0% 51 8.9% 24 9.4% 9 8.5% .9523
Mitoxantrone 1 0.1% 0 0.0% 1 0.4% 0 0.0% .3867
Natalizumab 85 9.1% 41 7.1% 28 11.0% 16 15.1% .0149
Rituximab 3 0.2% 2 0.2% 1 0.2% 0 0.0% 1.0000
No DMT use 661 41.3% 355 38.1% 186 42.1% 120 53.1% .0002
Baclofen 260 16.3% 95 10.2% 97 22.1% 68 30.1% <.0001
Relapse
Patients with a relapse in inpatient or outpatient setting (n, %) 255 15.9% 102 11.0% 87 19.7% 66 29.2% <.0001
Number of relapses in all patients
Mean 0.4 0.2 0.5 0.9 <.0001
SD 1.5 1.2 1.5 2.2
Median 0.0 0.0 0.0 0.0
MS-related symptoms and secondary conditions (n, %)
Anxiety 178 11.2% 84 9.1% 62 14.1% 32 14.2% .0065
Depression 317 19.9% 151 16.3% 108 24.6% 58 25.7% <.0001
Eye symptoms 55 3.5% 14 1.5% 23 5.2% 18 8.0% <.0001
Fatigue 415 26.1% 181 19.5% 140 31.9% 94 41.6% <.0001
Fractures 6 0.4% 1 0.1% 5 1.1% 0 0.0% .0157
Irritable bowel syndrome 30 1.9% 14 1.5% 10 2.3% 6 2.7% .4059
Muscular weakness 139 8.7% 0 0.0% 91 20.7% 48 21.2% <.0001
Osteoporosis 67 4.2% 23 2.5% 28 6.3% 16 7.1% .0002
Pyramidal symptoms 229 14.4% 0 0.0% 164 37.4% 65 28.8% <.0001
Sensory problems 323 20.3% 147 15.8% 118 26.9% 58 25.7% <.0001
Sleep disturbance 167 10.5% 70 7.5% 61 13.9% 36 15.9% <.0001
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increasing CDS, indicating a need for more treatment options
in patients with severe disability. Studies have shown that
current DMTs are not clinically effective in patients with
EDSS  6.519. A survey of 26 neurologists with expert know-
ledge of MS in Europe, North America and New Zealand
found that nearly 60% of surveyed neurologists preferred to
stop DMTs at an EDSS between 6.0 and 8.0. Some indicated
that third-party reimbursement is a factor in discontinuing
DMTs at certain levels of EDSS20. Most recently, a consensus
paper by the MS coalition concluded that access to DMTs
should not be limited by level of disability21, which is a shift
from prior recommendations, possibly due to the approval of
newer therapies indicated for a more progressed patient
population22.
In summary, this is the first published US study using
claims in combination with EMR data to develop a score
measuring MS disability level, an important indicator of MS
progression, using all eight functional systems of the EDSS.
In alignment with prior research, healthcare costs steadily
increase with increasing CDS level. The CDS advances the
opportunity to examine treatment patterns and outcomes by
disability accumulation in the absence of standard markers
of disease progression. However, this study has several limi-
tations. First, while EDSS is routinely used in clinical trials, it
is not typically collected in clinical practice; therefore, it was
only available in a small portion of patients in the EMR data-
base. Only four patients (0.3%) in the core sample had an
EDSS available, thus formal validation of the CDS was not
conducted. The level of disability for study patients was esti-
mated using proxies for ambulation/functional status in
claims or vitals/problem lists in the EMR. While the claims
coding was expected to be specific, the use of relevant
codes may not confer sensitivity in the grouping approach
used in this study. Thus, these proxies and the final deter-
mination of accuracy of the disability designation were
established in conjunction with clinical ME input and review.
These proxies were intended to categorize patients solely for
the research purposes in this study. They do not represent a
clinical designation and may be challenged by external
stakeholders. The CDS is a static measure of patient disability
and may inaccurately designate a severity level to patients
who are in the midst of a relapse during the CDS measure-
ment period. Despite these limitations, we believe this meth-
odology captured our intention to assess the viability of
utilizing real-world data sources to identify patient disability
level. Second, the ambulatory EMR includes only data cap-
tured from physicians contributing to the EMR network.
Patients that have vitals measurements (e.g. visual disturb-
ance, tactile sensation) taken by health care providers out-
side of the network are not captured. This could lead to a
limitation of generalizability of our findings. Third,
PharMetrics Plus data are sourced primarily from employer-
sponsored commercial and self-insured plans, and as such
underrepresent patients older than 65 years of age, specific-
ally those with fee-for-service Medicare, thus limiting the
generalizability of the study in older adults. This is an import-
ant limitation since MS is a chronic condition that is typically
diagnosed in working-age adults, and ultimately leads to
disability, which may then invoke Medicare coverage. Fourth,
this analysis is retrospective in nature and relies upon exist-
ing coding in claims data and narrative text in EMR that
were not collected for research purposes to approximate dis-
ability level. In addition, the IQVIA patient claims and EMR
datasets apply a proprietary linkage methodology and as
such cannot be made fully transparent. As a result, complete
verification of the linkage cannot be ascertained and the
possibility of error in linkage may exist. Lastly, indirect costs
and direct non-medical costs associated with MS were not
captured in the databases. Prior studies have found that
while direct medical costs are important contributors in the
earlier stages of MS, indirect costs outweigh direct medical
costs in later stages5,6. Future studies validating the CDS
are warranted.
Note
i. PharMetrics Plus is a registered trademark of IQVIA, Plymouth Meeting,
PA, USA.
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